Loading…
Tandem Diabetes Care, Inc. is projected to decline to $14.62 by 2027, a -5% move from its current price of $15.41. TNDM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $14.88 | $15.40 | $15.94 | -0.05% |
| Jul 15 | $14.66 | $15.39 | $16.16 | -0.10% |
| Jul 16 | $14.50 | $15.39 | $16.33 | -0.15% |
| Jul 17 | $14.36 | $15.38 | $16.48 | -0.20% |
| Jul 18 | $14.23 | $15.37 | $16.60 | -0.25% |
| Jul 19 | $14.12 | $15.36 | $16.72 | -0.30% |
| Jul 20 | $14.02 | $15.36 | $16.82 | -0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.02 | $15.36 | $16.82 | -0.35% |
| Week 2 | $13.45 | $15.30 | $17.41 | -0.71% |
| Week 3 | $13.02 | $15.25 | $17.85 | -1.06% |
| Week 4 | $12.66 | $15.19 | $18.23 | -1.41% |
| Week 5 | $12.35 | $15.14 | $18.56 | -1.75% |
| Week 6 | $12.07 | $15.09 | $18.86 | -2.10% |
| Week 7 | $11.81 | $15.03 | $19.13 | -2.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. Its flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system.
The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data.
The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc.
in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Tandem Diabetes Care, Inc. (TNDM) trades at current price $15.76, with a market cap of $1.08B and a rank of 2492.
The near-term picture is mixed, with a bearish technical stance reflected in its indicators. The RSI14 sits at 50, while the stock trades below the SMA50 ($17.22) and SMA200 ($18.57). The 30-day range spans $11.88 to $20.91, and traders note a support at $12.82 and resistance at $19.45.
Looking further out, the multi-year forecast moves into bullish territory from 2030 onward, with projected averages rising from $19.76 in 2030 to higher levels by the mid-2030s and beyond. The longer-horizon outlook features increasingly higher averages and ROIs, supported by notably higher projected prices in 2040 and 2050.
A major floor 26.7% below — a decisive break under it would weaken the trend.
The nearest floor, 6.9% below — buyers have tended to step in here.
The nearest ceiling, 26.2% above — a clean break opens room to run.
A major ceiling 62.8% above — clearing it would confirm fresh momentum.
Key TNDM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TNDM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.36 | Buy | $15.38 | Buy |
| MA 10 | $15.50 | Sell | $15.45 | Sell |
| MA 20 | $15.56 | Sell | $15.70 | Sell |
| MA 50 | $16.27 | Sell | $16.65 | Sell |
| MA 100 | $19.03 | Sell | $17.76 | Sell |
| MA 200 | $18.72 | Sell | $18.79 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.06 | Neutral |
| Stoch RSI (14) | 72.90 | Neutral |
| CCI (20) | -19.37 | Neutral |
| Williams %R (14) | -43.68 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 6.94 | Buy |
| Bollinger %B (20,2) | 0.44 | Neutral |
| Stochastic %K (14) | 56.32 | Neutral |
| TRIX (15) | -0.35 | Sell |
| Awesome (5,34) | -0.88 | Sell |
| Ultimate (7,14,28) | 54.80 | Neutral |
| Momentum (10) | -0.35 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 15.28 | Buy |
| ADX (14) | 11.82 | Neutral |
| ATR (14) | 0.48 | Info |
The 30-day technical picture shows bearish sentiment with RSI 50, and the price below both the SMA50 ($17.22) and SMA200 ($18.57).
The 30-day price range runs from $11.88 to $20.91, with a defined support at $12.82 and resistance at $19.45.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.82 | $15.41 | $17.56 | 0% | Neutral | |
| $11.36 | $14.62 | $20.07 | -5% | Neutral | |
| $10.40 | $13.88 | $19.92 | -10% | Neutral | |
| $10.59 | $14.56 | $21.66 | -5% | Neutral | |
| $12.57 | $17.77 | $27.20 | +15% | Neutral | |
| $13.24 | $19.17 | $30.11 | +24% | Bullish | |
| $13.53 | $20.05 | $32.21 | +30% | Bullish | |
| $12.67 | $19.20 | $31.48 | +25% | Bullish | |
| $11.95 | $18.48 | $30.88 | +20% | Neutral | |
| $12.97 | $20.46 | $34.79 | +33% | Bullish | |
| $16.14 | $27.93 | $51.05 | +81% | Bullish | |
| $24.54 | $50.06 | $101.54 | +225% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $12.82 | $15.41 | $18.50 | +0.00% |
| August 2026 | $12.52 | $14.88 | $18.22 | -3.45% |
| September 2026 | $12.27 | $14.72 | $18.28 | -1.10% |
| October 2026 | $12.30 | $14.85 | $18.67 | +0.95% |
| November 2026 | $11.79 | $14.33 | $18.19 | -3.51% |
| December 2026 | $11.21 | $13.71 | $17.56 | -4.32% |
Click any year to see its month-by-month TNDM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Tandem Diabetes Care, Inc.'s 2026 outlook centres on $15.41, within a $12.82 to $17.56 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TNDM could reach as high as $20.07, with a base case around $14.62 and support toward $11.36 — roughly -5% from $15.41. A consolidation phase looks the most probable path here.
Expect TNDM to range from $10.40 to $19.92 through 2028. The $13.88 average target implies a -10% move from current prices. That is -5% versus the projected 2027 average. Price action looks broadly range-bound.
The TNDM price prediction for 2029 points to an average of $14.56 (low $10.59, high $21.66) — a potential decline of -5% on today's $15.41. A consolidation phase looks the most probable path here.
In 2030, TNDM is projected to trade between $12.57 and $27.20, averaging $17.77 — a potential gain of +15% from today's $15.41. That is up +22% on the projected 2029 average. Price action looks broadly range-bound.
Tandem Diabetes Care, Inc.'s 2031 outlook centres on $19.17, within a $13.24 to $30.11 range. That is up +8% on the projected 2030 average. That marks a +24% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TNDM could reach as high as $32.21, with a base case around $20.05 and support toward $13.53 — roughly +30% from $15.41. Momentum favours further upside here.
Expect TNDM to range from $12.67 to $31.48 through 2033. The $19.20 average target implies a +25% move from current prices. That is -4% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The TNDM price prediction for 2034 points to an average of $18.48 (low $11.95, high $30.88) — a potential gain of +20% on today's $15.41. Price action looks broadly range-bound.
In 2035, TNDM is projected to trade between $12.97 and $34.79, averaging $20.46 — a potential gain of +33% from today's $15.41. That is up +11% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Tandem Diabetes Care, Inc.'s 2040 outlook centres on $27.93, within a $16.14 to $51.05 range. That is up +37% on the projected 2035 average. That marks a +81% change versus current levels. Momentum favours further upside here.
By 2050, TNDM could reach as high as $101.54, with a base case around $50.06 and support toward $24.54 — roughly +225% from $15.41. Buyers look set to stay in control over this stretch.
Investing $1,000 in TNDM today (≈ 64.892927 TNDM) could be worth
$3,248.75
+$2,248.75 (+225%) by 2050 · US Dollar
Based on the average projected TNDM price of $50.06 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TNDMwould be worth at today's price.
$1,000 invested in TNDM on Jul 10, 2025 (≈ 61.842919 TNDM) would be worth
$953
-$47 (-4.7%) today · 0.95× · US Dollar
Based on a TNDM entry price of $16.17 vs. today's $15.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.32 | $1,005.87 | +0.6% |
| 1 month ago | $16.23 | $949.48 | -5.1% |
| 3 months ago | $19.18 | $803.44 | -19.7% |
| 6 months ago | $21.35 | $721.78 | -27.8% |
| 1 year ago | $16.17 | $953 | -4.7% |
| All time (5.0y) ago | $93.51 | $164.8 | -83.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TNDM forecast.
Our base-case forecast reaches $31.00 around 2050.
Implied market cap at $31.00: $2.12B
The multi-year forecast turns bullish in 2030, with an average price of $19.76 and a range from $13.18 to $32.11. The projected ROI is 25.4 and sentiment is BULLISH. In 2031 the average is $20.32 with ROI 28.9, and in 2032 the average is $21.81 with ROI 38.4; 2033 shows an average of $20.51 with ROI 30.2.
The 2034 forecast is $18.61 (ROI 18.1; sentiment NEUTRAL) and 2035 is $23.11 (ROI 46.6; sentiment BULLISH).
By 2040 the forecast average is $29.74 with a max of $59.27 and ROI 88.7, and by 2050 the forecast average is $56.61 with a max of $126.96 and ROI 259.2, both with a BULLISH sentiment. The numbers reflect substantial upside potential in the long run, tempered by notable volatility (annualized volatility 80) and mixed near-term signals.
Tap a question to reveal the answer.
2030 avg price $19.76; min $13.18; max $32.11; ROI 25.4; sentiment BULLISH.
Near term shows neutral in 2026 with avg $15.76 and ROI 0; 2027 avg $15.16 with ROI -3.8; 2028 avg $13.52 with ROI -14.2; 2029 avg $15.13 with ROI -4.0. The forecast turns bullish from 2030 onward.
Yes. The 2040 max forecast is $59.27, with 2040 avg $29.74 and ROI 88.7.
$11.88 to $20.91.
Min $25.47; avg $56.61; max $126.96; ROI 259.2; sentiment BULLISH.
Tandem Diabetes Care, Inc. Community Discussion
0Share your Tandem Diabetes Care, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.